دورية أكاديمية
Analysis of pharma R&D productivitya new perspective needed
| العنوان: | Analysis of pharma R&D productivitya new perspective needed |
|---|---|
| المؤلفون: | Schuhmacher, Alexander, Hinder, Markus, Von Stegmann Und Stein, Alexander, Hartl, Dominik, Gassmann, Oliver |
| سنة النشر: | 2023 |
| المجموعة: | University of St. Gallen: Research Platform Alexandria |
| مصطلحات موضوعية: | big pharma, drug discovery, R&D, R&D efficiency, R&D effectiveness, R&D productivity |
| الوصف: | R&D productivity continues to be the industry's grand challenge. We analyzed the R&D input, output, and outcome of 16 leading research-based pharmaceutical companies over 20 years (2001-2020). Our analysis shows that pharma companies increased their R&D spending at a compound annual growth rate of 6% (2001-2020) to an average R&D expenditure per company of $6.7 billion (2020). The companies in our investigation launched 251 new drugs representing 46% of all CDER-related FDA approvals in the past 20 years. The average R&D efficiency of big pharma was $6.16 billion total R&D expenditures per new drug. Almost half of the leading companies needed to compensate for their negative R&D productivity through mergers and acquisitions. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | Drug Discovery Today; 10; https://www.alexandria.unisg.ch/handle/20.500.14171/117987Test |
| DOI: | 10.1016/j.drudis.2023.103726 |
| الإتاحة: | https://doi.org/10.1016/j.drudis.2023.103726Test https://doi.org/20.500.14171/117987Test https://www.alexandria.unisg.ch/handle/20.500.14171/117987Test https://hdl.handle.net/20.500.14171/117987Test |
| حقوق: | openaccess |
| رقم الانضمام: | edsbas.F250FC63 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1016/j.drudis.2023.103726 |
|---|